Search results for "Adrenergic"

showing 10 items of 433 documents

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic…

2015

Inhaled corticosteroids (ICS) are frequently recommended for the treatment of asthma and COPD, often in combination with long-acting beta2-agonists (LABA), depending on the severity of the disease and/or on the specific phenotype. Several ICS/LABA combinations are currently available that differ in their pharmacokinetic characteristics and dose of both components. Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. Whereas the basic mechanism of action is similar for all ICS (binding with the intracellular gluco…

BudesonideAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioBudesonide; COPD; Fluticasone; Pneumonia; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Drug Combinations; Glucocorticoids; Humans; Pulmonary Disease Chronic Obstructive; Quality of Life; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)Pulmonary DiseasePulmonary Disease Chronic ObstructiveGlucocorticoidInternal medicineDrug CombinationAdministration InhalationmedicineBudesonide; COPD; Fluticasone; Pneumonia; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical)HumansCOPDPharmacology (medical)educationBudesonideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAsthmaFluticasoneeducation.field_of_studyCOPDbusiness.industryBiochemistry (medical)Pneumoniamedicine.diseaserespiratory tract diseasesDrug CombinationsInhalationAnesthesiaAdministrationQuality of LifeCorticosteroidFluticasoneFormoterolSalmeterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHuman
researchProduct

Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.

2007

An inhaled corticosteroid (ICS) or an ICS/long-acting beta(2)-agonist (LABA) combination plus short-acting beta(2)-agonist (SABA) as needed for symptom relief is recommended for persistent asthma. Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort SMART, AstraZeneca, Sweden) has been approved for adults in the European Union. This option is well tolerated and offers greater reductions in asthma exacerbations together with similar improvements in daily symptom control, at a lower overall steroid load, compared with fixed-dose ICS/LABA plus SABA.Two large clinical trials investigated the use of budesonide/formoterol as maintenance and reliever compared with medium…

BudesonideAdultMalemedicine.medical_specialtyAdolescentlaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicineFormoterol Fumaratemedicinemedia_common.cataloged_instanceHumansAnti-Asthmatic AgentsEuropean unionBudesonidemedia_commonAsthmaAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeBudesonide/formoterolEthanolaminesPhysical therapyFormoterol FumarateDrug Therapy CombinationFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCurrent medical research and opinion
researchProduct

Overall asthma control: the relationship between current control and future risk.

2009

Background Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler ∗ ∗Symbicort SMART and Turbuhaler are trademarks owned by AstraZeneca. Neither the Symbicort SMART posology nor the dry powder formulation Turbuhaler are currently approved in the United States.) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods The perc…

BudesonideAdultMalemedicine.medical_specialtyExacerbationAdolescentImmunologyYoung AdultAdrenal Cortex HormonesInternal medicineFormoterol FumarateSurveys and QuestionnairesAdministration InhalationmedicineImmunology and AllergyBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsRisk factorBudesonideChildAsthmaAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overInhalationbusiness.industryAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseAsthmaMarkov ChainsDrug CombinationsAsthma Control QuestionnaireEthanolaminesChild PreschoolPractice Guidelines as TopicPhysical therapyFormoterol FumarateFemaleFormoterolbusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Th17 immunity in children with allergic asthma and rhinitis: a pharmacological approach

2013

Th17 cells and IL-17A play a role in the development and progression of allergic diseases. We analyzed the IL-17A levels in sputum supernatants (Ss), nasal wash (NW) and plasma (P) from Healthy Controls (HC) and children with Asthma/Rhinitis. We tested the expression of IL-17A, RORγ(t) and FOXP3 in peripheral blood T-lymphocytes from intermittent and mild-moderate asthma. The effect of Budesonide and Formoterol was tested "in vitro" on IL-17A, RORγ(t) and FOXP3 expression in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis patients, and on nasal and bronchial epithelial cells stimulated with NW and Ss from mild-moderate asthma/persistent rhinitis. Further, the effect of …

BudesonideMalePulmonologyIL 13 and AsthmaGene ExpressionAnti-asthmatic AgentBiochemistryPediatricsimmune system diseasesFormoterol FumarateMolecular Cell BiologyAnti-Asthmatic AgentsBudesonideChildCells CulturedMultidisciplinaryImmune System ProteinsQInterleukin-17RFOXP3Forkhead Transcription FactorsNuclear Receptor Subfamily 1 Group F Member 3EthanolaminesMedicineFemaleInterleukin 17medicine.symptommedicine.drugResearch ArticleRhinitis Allergic PerennialAdolescentScienceImmunologyPediatric PulmonologyInflammationAdministration InhalationmedicineHumansAdrenergic beta-2 Receptor AgonistsBiologyAsthmaInflammationbusiness.industryInterleukin-8SputumImmunityProteinsImmunologic Subspecialtiesmedicine.diseaseNasal Lavage FluidAsthmarespiratory tract diseasesCase-Control StudiesImmunologySputumTh17 CellsClinical ImmunologyFormoterolbusinessPulmonary Immunology
researchProduct

Ischemic stroke increases heart vulnerability to ischemia-reperfusion and alters myocardial cardioprotective pathways

2018

Background and Purpose— For years, the relationship between cardiac and neurological ischemic events has been limited to overlapping pathophysiological mechanisms and common risk factors. However, acute stroke may induce dramatic changes in cardiovascular function. The aim of this study was to evaluate how prior cerebrovascular lesions affect myocardial function and signaling in vivo and ex vivo and how they influence cardiac vulnerability to ischemia-reperfusion injury. Methods— Cerebral embolization was performed in adult Wistar male rats through the injection of microspheres into the left or right internal carotid artery. Stroke lesions were evaluated by microsphere counting, tissue sta…

Cardiac function curveMalemedicine.medical_specialtySympathetic nervous systemGrowth Differentiation Factor 15Myocardial ischemiaNitro-oxidative stressHeart VentriclesIschemiaMyocardial Infarction030204 cardiovascular system & hematologyContractility03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIn vivoInternal medicinemedicineAnimalsRats WistarStrokeIschemic StrokeAdvanced and Specialized Nursingbusiness.industryMyocardiumBrainIsolated Heart PreparationHeartmedicine.diseaseRatsStrokeAutonomic nervous systemOxidative Stressmedicine.anatomical_structureEchocardiographyNitrosative StressReperfusion InjuryCardiologyNeurology (clinical)Disease SusceptibilityReceptors Adrenergic beta-1Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryEx vivoAutonomic nervous system Subject terms: Ischemia
researchProduct

Ability of short-time Fourier transform method to detect transient changes in vagal effects on hearts: a pharmacological blocking study.

2006

Conventional spectral analyses of heart rate variability (HRV) have been limited to stationary signals and have not allowed the obtainment of information during transient autonomic cardiac responses. In the present study, we evaluated the ability of the short-time Fourier transform (STFT) method to detect transient changes in vagal effects on the heart. We derived high-frequency power (HFP, 0.20–0.40 Hz) as a function of time during active orthostatic task (AOT) from the sitting to standing posture before and after selective vagal (atropine sulfate 0.04 mg/kg) and sympathetic (metoprolol 0.20 mg/kg) blockades. The HFP minimum point during the first 30 s after standing up was calculated and…

Cardiac responseAdultAtropineMalemedicine.medical_specialtySympathetic Nervous SystemPhysiologyAdrenergic beta-AntagonistsPostureBlood PressureMuscarinic AntagonistsDizzinessOrthostatic vital signsPhysiology (medical)Internal medicinemedicineHeart rate variabilityHumansFourier AnalysisChemistryBlocking (radio)Short-time Fourier transformHeartVagus NerveAutonomic AgentsTime–frequency analysisSurgeryAutonomic nervous systemCardiologyTransient (oscillation)Cardiology and Cardiovascular MedicineMetoprololAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, str…

2003

Background: the effects of long-term administration of β-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial. Patients and methods: patients with stable congestive heart failure (CHF) (New York heart association [NYHA] class II and III) and ejection fraction (EF) ≤0.40 were randomized to metoprolol, 50 mg t.i.d. or placebo for 6 months. Patients were divided into two groups: ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM). The mean EF was 0.29 in both groups and 92% were taking angiotensin-converting enzyme (ACE) inhibitors. In the IHD group, 84% had su…

Cardiomyopathy DilatedMalemedicine.medical_specialtyTime FactorsAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyRadionuclide angiographyDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathymedicineHumanscardiovascular diseasesMyocardial infarctionExerciseMetoprololEjection fractionVentricular Remodelingmedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyGated Blood-Pool ImagingHeartStroke VolumeAtrial fibrillationMiddle Agedmedicine.diseaseHeart failureExercise TestCardiologyFemaleCardiology and Cardiovascular MedicinebusinessMetoprololmedicine.drugEuropean Journal of Heart Failure
researchProduct

Selectivity of pharmacological tools: implications for use in cell physiology. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanis…

2014

Pharmacological inhibitors are frequently used to identify the receptors, receptor subtypes, and associated signaling pathways involved in physiological cell responses. Based on the effects of such inhibitors conclusions are drawn about the involvement of their assumed target or lack thereof. While such inhibitors can be useful tools for a better physiological understanding, their uncritical use can lead to incorrect conclusions. This article reviews the concept of inhibitor selectivity and its implication for cell physiology. Specifically, we discuss the implications of using inhibitor vs. activator approaches, issues of direct vs. indirect pathway modulation, implications of inverse agoni…

Cell physiologyCell signalingPhysiologyAdrenergic beta-AntagonistsCellAllosteric regulationImidazolesCell CommunicationCell BiologyAdrenergic beta-AgonistsBiologyPharmacologyIndirect pathway of movementCell Physiological PhenomenaReceptors G-Protein-CoupledFunctional antagonismmedicine.anatomical_structuremedicineAnimalsHumansSignal transductionReceptorNeuroscienceProtein BindingSignal TransductionAmerican Journal of Physiology-Cell Physiology
researchProduct

A systematic review of inverse agonism at adrenoceptor subtypes

2020

As many, if not most, ligands at G protein-coupled receptor antagonists are inverse agonists, we systematically reviewed inverse agonism at the nine adrenoceptor subtypes. Except for β3-adrenoceptors, inverse agonism has been reported for each of the adrenoceptor subtypes, most often for β2-adrenoceptors, including endogenously expressed receptors in human tissues. As with other receptors, the detection and degree of inverse agonism depend on the cells and tissues under investigation, i.e., they are greatest when the model has a high intrinsic tone/constitutive activity for the response being studied. Accordingly, they may differ between parts of a tissue, for instance, atria vs. ventricles…

Cell typeDrug Inverse AgonismAdrenergic receptorDrug discoveryChemistryinverse agonismReviewpharmacology_toxicology570 Life sciencesBasal (phylogenetics)lcsh:Biology (General)Drug DevelopmentDrug developmentHumansInverse agonistAgonismReceptors Adrenergic beta-2Receptorlcsh:QH301-705.5adrenoceptorconstitutive activityNeuroscience570 Biowissenschaften
researchProduct

Leukocyte Redistribution: Effects of Beta Blockers in Patients with Chronic Heart Failure

2009

BACKGROUND:Overproduction of pro-inflammatory cytokines is a well established factor in the progression of chronic heart failure (CHF). Changes in cellular immunity have not been widely studied, and the impact of standard medication is uncertain. Here we investigate whether a leukocyte redistribution occurs in CHF and whether this effect is influenced by beta-blocker therapy. METHODOLOGY:We prospectively studied 75 patients with systolic CHF (age: 68+/-11 years, left ventricular ejection fraction 32+/-11%, New York Heart Association class 2.5+/-0.7) and 20 age-matched healthy control subjects (age: 63+/-10 years). We measured the response of cells to endotoxin exposure in vitro, analysed su…

Cellular immunityAdrenergic beta-AntagonistsCardiovascular Disorders/Heart Failurelcsh:MedicineVentricular Function LeftAdrenergic beta-AntagonistsLeukocytesHumansMedicineIn patientProspective Studiescardiovascular diseaseslcsh:ScienceProspective cohort studyAgedHeart FailureMultidisciplinaryVentricular functionbusiness.industrylcsh:RCase-control studyMiddle AgedFlow Cytometrymedicine.diseaseCase-Control StudiesImmunology/Leukocyte ActivationHeart failureImmunologylcsh:QbusinessImmunology/Leukocyte DevelopmentResearch ArticlePLoS ONE
researchProduct